Primary and Secondary Prevention of Cardiovascular Disease in Older Adults: A Status Report

Clinics in Geriatric Medicine

Volumn 25, Issue 4, 2009, Pages 745-755

  Kriekard, Peter ^a   Gharacholou, S Michael ^a   Peterson, Eric D ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Division of Cardiology   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Cardiovascular disease; Older adults; Prevention; Risk factors; Status

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CARVEDILOL; CHLORTALIDONE; CLOPIDOGREL; DOXAZOSIN; INDAPAMIDE; LISINOPRIL; LOSARTAN; METOPROLOL; PERINDOPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN;

AGED; BLEEDING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; ELDERLY CARE; EXERCISE; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; STROKE; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOOD HABITS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; LIFE STYLE; MALE; PLATELET AGGREGATION INHIBITORS; POPULATION DYNAMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SMOKING CESSATION; UNITED STATES;

EID: 70449864787     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2009.07.008     Document Type: Review

References (42)

1. American Heart Association. Heart disease and stroke statistics-2009 update (2009), American Heart Association, Dallas (TX)
2. U.S. Census Bureau. US population projections. Available at:. http://www.census.gov/population/www/projections/summarytables.html Accessed April 8, 2009
3. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113 (2006) 791-798
4. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
5. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III). JAMA 285 (2001) 2486-2497
6. Ostchega Y., Dillon C.F., Hughes J.P., et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 55 (2007) 1056-1065
7. Ostchega Y., Toon S.S., Hughes J., et al. Hypertension awareness, treatment, and control - continued disparities in adults: United States, 2005-2006. NCHS data brief no (2008), National Center for Health Statistics, Hyattsville (MD)
8. Chobanian A.V. Isolated systolic hypertension in the elderly. N Engl J Med 357 (2007) 789-796
9. Izzo Jr. J.L., Levy D., and Black H.R. Clinical advisory statement. Importance of systolic blood pressure in older Americans. Hypertension 35 (2000) 1021-1024
10. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265 (1991) 3255-3264
11. Patel A.P., Kostis J.B., Wilson A.C., et al. Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the Systolic Hypertension in the Elderly Program (SHEP). Stroke 39 (2008) 1084-1089
12. Oates D.J., Berlowitz D.R., Glickman M.E., et al. Blood pressure and survival in the oldest old. J Am Geriatr Soc 55 (2007) 383-388
13. Gueyffier F., Bulpitt C., Boissel J.P., et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials (INDIANA). Lancet 353 (1999) 793-796
14. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older (HYVET). N Engl J Med 358 (2008) 1887-1898
15. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 288 (2002) 2981-2997
16. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
17. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrocholorthiazide for hypertension in high-risk patients. N Engl J Med 359 (2008) 2417-2428
18. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. BMJ 336 (2008) 1121-1123
19. Schober S.E., Carroll M.D., Lacher D.A., et al. High serum total cholesterol - an indicator of monitoring cholesterol lowering efforts; U.S. adults, 2005-2006. NCHS data brief no 2 (2007), National Center for Health Statistics, Hyattsville (MD)
20. Shepherd J., Cobbe S., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group (WOSCOPS). N Engl J Med 333 (1995) 1301-1307
21. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
22. Weverling-Rijnsburger A.W., Blauw G.J., Lagaay A.M., et al. Total cholesterol and risk of mortality in the oldest old. Lancet 350 (1997) 1119-1123
23. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
24. Miettinen T.A., Pyorala K., Olsson A.G., et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 96 (1997) 4211-4218
25. Shepherd J., Blauw G.J., Murphy M.B., et al. PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized trial. Lancet 360 (2002) 1623-1630
26. Ridker P.M., Danielson M., Fonseca F., et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
27. Michos E.D., and Blumenthal R.S. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the US. J Am Coll Cardiol 53 (2009) 931-935
28. Heart Protection Study (HPS) Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
29. Ray K.K., Bach R.G., Cannon C.P., et al. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J 27 (2006) 2310-2316
30. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
31. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
32. Peters R.J., Mehta S.R., Fox K.A.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. Circulation 108 (2003) 1682-1687
33. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 7 (2001) 494-502
34. Bhatt D.L., Fox K.A.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
35. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 342 (2000) 145-153
36. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 283 (2000) 1295-1302
37. Packer M., Fowler M.B., Roecker E.L., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
38. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The CAPRICORN Investigators. Lancet 357 (2001) 1385-1390
39. Sparrow D., Dawber T., and Colton T. The influence of cigarette smoking on prognosis after first myocardial infarction. J Chronic Dis 31 (1978) 415-432
40. Hermanson B., Omenn G.S., Kronmal R.A., et al. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease: results from the CASS registry. N Engl J Med 319 (1988) 1365-1369
41. Williams M.A., Flegg J.L., Ades P.A., et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥ 75 years of age). Circulation 105 (2002) 1735-1743
42. U.S. Department of Health and Human Services. Health People 2010: Understanding and Improving Health. 2nd edition. Washington, DC: US Government Printing Office. November 2000.